IE
OPNT

Israel Englander’s Opiant Pharmaceuticals, Inc. Common Stock OPNT Stock Holding History

Israel Englander’s Portfolio OPNT Stock Details OPNT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-11,577
Closed -$248K – 7766
2022
Q1 		$248K Buy
+11,577
New +$307K ﹤0.01% 5708

Other funds holding OPNT

HP
HealthInvest Partners Stockholm, Sweden $372M AUM 59.89% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $617B AUM 30.33% 1-Year Est. Return
ACA
Apis Capital Advisors New York $1.03B AUM 383.18% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
SCM
Stonepine Capital Management Bend, Oregon $177M AUM 91.13% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
PHP
Parkman Healthcare Partners Stamford, Connecticut $977M AUM 110.37% 1-Year Est. Return
Two Sigma Advisers
Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return

Israel Englander's OPNT Position: Q2 2022 in Review

Israel Englander sold out of Opiant Pharmaceuticals, Inc. Common Stock (OPNT) in Q2 2022, closing a stake of 11,577 shares — an estimated $248K sold.

Israel Englander first reported a position in OPNT in Q1 2022 and held it in 1 quarter. The position peaked at $248K in Q1 2022. 33 funds tracked by Wall St. Rank hold OPNT as of Q2 2022.

  • Israel Englander reported no remaining Opiant Pharmaceuticals, Inc. Common Stock position as of Q2 2022 after selling out during the quarter.
  • Israel Englander sold 11,577 Opiant Pharmaceuticals, Inc. Common Stock shares in Q2 2022, an estimated $248K.
  • Israel Englander first reported a position in Opiant Pharmaceuticals, Inc. Common Stock in Q1 2022 and held it in 1 quarter.
  • Israel Englander's Opiant Pharmaceuticals, Inc. Common Stock position peaked at $248K in Q1 2022.
  • 33 funds tracked by Wall St. Rank held Opiant Pharmaceuticals, Inc. Common Stock as of Q2 2022.

Based on Millennium Management's 13F filing for Q2 2022, filed 15 Aug 2022.